Literature DB >> 7832434

In vivo generation of hydroxyl radicals and MPTP-induced dopaminergic toxicity in the basal ganglia.

C C Chiueh1, R M Wu, K P Mohanakumar, L M Sternberger, G Krishna, T Obata, D L Murphy.   

Abstract

The in vivo generation of .OH free radicals in specific brain regions can be measured by intracerebral microdialysis perfusion of salicylate, avoiding many of the pitfalls inherent in systemic administration of salicylate. Direct infusion of salicylate into the brain can minimize the hepatic hydroxylation of salicylate and its contribution to brain levels of 2,5-DHBA. Levels of 2,5-DHBA detected in the brain dialysate may reflect the .OH adduct plus some enzymatic hydroxylation of salicylate in the brain. After minimizing the contribution of enzyme and/or blood-borne 2,5-DHBA, the present data demonstrate the validity of the use of 2,3-DHBA and apparently 2,5-DHBA as indices of .OH formation in the brain. Therefore, intracranial microdialysis of salicylic acid and measurement of 2,3-DHBA appears to be a useful .OH trapping procedure for monitoring the time course of .OH generation in the extracellular fluid of the brain. These results indicate that nonenzymatic and/or enzymatic oxidation of the dopamine released by MPTP analogues in the extracellular fluid may play a key role in the generation of .OH free radicals in the iron-rich basal ganglia. Moreover, a site-specific generation of cytotoxic .OH free radicals and quinone/semiquinone radicals in the striatum may cause the observed lipid peroxidation, calcium overload, and retrograde degeneration of nigrostriatal neurons. This free-radical-induced nigral injury can be suppressed by antioxidants (i.e., U-78517F, DMSO, and deprenyl) and possibly hypothermia as well. In the future, this in vivo detection of .OH generation may be useful in answering some of the fundamental questions concerning the relevance of oxidants and antioxidants in neurodegenerative disorders during aging. It could also pave the way for the research and development of novel neuroprotective antioxidants and strategies for the early or preventive treatment of neurodegenerative disorders, such as Parkinson's disease (Wu et al., this issue), amyotrophic lateral sclerosis, head trauma, and possibly Alzheimer's cognitive dysfunction as well. In conclusion, this in vivo free-radical trapping procedure provides evidence to support a current working hypothesis that a site-specific formation of cytotoxic .OH free radicals in the basal ganglia may be one of the neurotoxic mechanisms underlying nigrostriatal degeneration and Parkinsonism caused by the dopaminergic neurotoxin MPTP. Addendum added in proof: The controversy concerning possible neurotoxic and/or neuroprotective roles of NO. in cell cultures was discussed and debated at the symposium (Wink et al., this issue; Dawson et al., this issue; Lipton et al., this issue).(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7832434     DOI: 10.1111/j.1749-6632.1994.tb21786.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  12 in total

Review 1.  Pharmacological treatment of Parkinson's disease.

Authors:  A Münchau; K P Bhatia
Journal:  Postgrad Med J       Date:  2000-10       Impact factor: 2.401

2.  Biochemical and physiological evidence that carnosine is an endogenous neuroprotector against free radicals.

Authors:  A A Boldyrev; S L Stvolinsky; O V Tyulina; V B Koshelev; N Hori; D O Carpenter
Journal:  Cell Mol Neurobiol       Date:  1997-04       Impact factor: 5.046

3.  Systems pharmacogenomics - gene, disease, drug and placebo interactions: a case study in COMT.

Authors:  Kathryn T Hall; Joseph Loscalzo; Ted J Kaptchuk
Journal:  Pharmacogenomics       Date:  2019-05       Impact factor: 2.533

4.  Evidence for hydroxyl radical scavenging action of nitric oxide donors in the protection against 1-methyl-4-phenylpyridinium-induced neurotoxicity in rats.

Authors:  Rebecca Banerjee; Karuppagounder S Saravanan; Bobby Thomas; Kizhake M Sindhu; Kochupurackal P Mohanakumar
Journal:  Neurochem Res       Date:  2007-09-01       Impact factor: 3.996

5.  Catechol is the major product of salicylate hydroxylation in 1-methyl-4-phenylpyridinium ion treated rats.

Authors:  E Sam; S Sarre; Y Michotte; N Verbeke
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Apr-Jun       Impact factor: 2.441

6.  Extracellular dopamine potentiates mn-induced oxidative stress, lifespan reduction, and dopaminergic neurodegeneration in a BLI-3-dependent manner in Caenorhabditis elegans.

Authors:  Alexandre Benedetto; Catherine Au; Daiana Silva Avila; Dejan Milatovic; Michael Aschner
Journal:  PLoS Genet       Date:  2010-08-26       Impact factor: 5.917

7.  The Role of skn-1 in methylmercury-induced latent dopaminergic neurodegeneration.

Authors:  Ebany J Martinez-Finley; Samuel Caito; James C Slaughter; Michael Aschner
Journal:  Neurochem Res       Date:  2013-11-06       Impact factor: 3.996

Review 8.  Proteomic approach to studying Parkinson's disease.

Authors:  Jing Zhang; David R Goodlett
Journal:  Mol Neurobiol       Date:  2004-06       Impact factor: 5.590

Review 9.  Nitric oxide and MPP+-induced hydroxyl radical generation.

Authors:  T Obata
Journal:  J Neural Transm (Vienna)       Date:  2006-02-06       Impact factor: 3.575

10.  Targeting the progression of Parkinson's disease.

Authors:  J L George; S Mok; D Moses; S Wilkins; A I Bush; R A Cherny; D I Finkelstein
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.